Chemclin Diagnostics Co. Ltd. A (688468) - Net Assets
Based on the latest financial reports, Chemclin Diagnostics Co. Ltd. A (688468) has net assets worth CN¥1.42 Billion CNY (≈ $207.77 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.76 Billion ≈ $258.12 Million USD) and total liabilities (CN¥344.10 Million ≈ $50.35 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore Chemclin Diagnostics Co. Ltd. A (688468) cash conversion ratio to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.42 Billion |
| % of Total Assets | 80.49% |
| Annual Growth Rate | 10.23% |
| 5-Year Change | 10.34% |
| 10-Year Change | N/A |
| Growth Volatility | 14.04 |
Chemclin Diagnostics Co. Ltd. A - Net Assets Trend (2017–2025)
This chart illustrates how Chemclin Diagnostics Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Also explore Chemclin Diagnostics Co. Ltd. A assets under control for the complete picture of this company's asset base.
Annual Net Assets for Chemclin Diagnostics Co. Ltd. A (2017–2025)
The table below shows the annual net assets of Chemclin Diagnostics Co. Ltd. A from 2017 to 2025. For live valuation and market cap data, see Chemclin Diagnostics Co. Ltd. A (688468) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.41 Billion ≈ $206.46 Million |
-0.38% |
| 2024-12-31 | CN¥1.42 Billion ≈ $207.25 Million |
+1.98% |
| 2023-12-31 | CN¥1.39 Billion ≈ $203.23 Million |
+0.60% |
| 2022-12-31 | CN¥1.38 Billion ≈ $202.02 Million |
+7.97% |
| 2021-12-31 | CN¥1.28 Billion ≈ $187.11 Million |
+44.10% |
| 2020-12-31 | CN¥887.36 Million ≈ $129.85 Million |
+2.35% |
| 2019-12-31 | CN¥866.97 Million ≈ $126.87 Million |
+11.81% |
| 2018-12-31 | CN¥775.38 Million ≈ $113.46 Million |
+19.83% |
| 2017-12-31 | CN¥647.08 Million ≈ $94.69 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Chemclin Diagnostics Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 55461801714.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥440.13 Million | 31.19% |
| Other Components | CN¥970.77 Million | 68.81% |
| Total Equity | CN¥1.41 Billion | 100.00% |
Chemclin Diagnostics Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Chemclin Diagnostics Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hanjia Design Croup Co Ltd Class A
SHE:300746
|
$390.45 Million |
|
Aydem Yenilenebilir Enerji AS
IS:AYDEM
|
$390.65 Million |
|
ASTON MART.LA.UADR LS-001
F:A5S0
|
$390.66 Million |
|
Morrow Bank ASA
OL:MOBA
|
$390.78 Million |
|
Mercurity Fintech Holding Inc ADR
NASDAQ:MFH
|
$390.29 Million |
|
Lyell Immunopharma Inc
NASDAQ:LYEL
|
$390.28 Million |
|
Fujian SBS Zipper Science Tech
SHE:002098
|
$390.28 Million |
|
Norske Skog Asa
OL:NSKOG
|
$390.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chemclin Diagnostics Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,416,307,137 to 1,410,895,513, a change of -5,411,624 (-0.4%).
- Net income of 44,407,600 contributed positively to equity growth.
- Dividend payments of 54,787,084 reduced retained earnings.
- Other comprehensive income decreased equity by 55,468,462.
- Other factors increased equity by 60,436,322.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥44.41 Million | +3.15% |
| Dividends Paid | CN¥54.79 Million | -3.88% |
| Other Comprehensive Income | CN¥-55.47 Million | -3.93% |
| Other Changes | CN¥60.44 Million | +4.28% |
| Total Change | CN¥- | -0.38% |
Book Value vs Market Value Analysis
This analysis compares Chemclin Diagnostics Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.90x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.06x to 1.90x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥3.22 | CN¥6.65 | x |
| 2018-12-31 | CN¥3.86 | CN¥6.65 | x |
| 2019-12-31 | CN¥4.32 | CN¥6.65 | x |
| 2020-12-31 | CN¥2.50 | CN¥6.65 | x |
| 2021-12-31 | CN¥3.31 | CN¥6.65 | x |
| 2022-12-31 | CN¥3.44 | CN¥6.65 | x |
| 2023-12-31 | CN¥3.49 | CN¥6.65 | x |
| 2024-12-31 | CN¥3.57 | CN¥6.65 | x |
| 2025-12-31 | CN¥3.49 | CN¥6.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chemclin Diagnostics Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.35%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.25x
- Recent ROE (3.15%) is above the historical average (-5.29%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -67.26% | -136.61% | 0.45x | 1.10x | CN¥-499.94 Million |
| 2018 | -54.71% | -115.90% | 0.43x | 1.10x | CN¥-501.78 Million |
| 2019 | 16.22% | 30.92% | 0.46x | 1.15x | CN¥53.90 Million |
| 2020 | 13.19% | 27.98% | 0.42x | 1.13x | CN¥28.28 Million |
| 2021 | 11.16% | 30.32% | 0.33x | 1.12x | CN¥14.89 Million |
| 2022 | 11.06% | 32.80% | 0.29x | 1.15x | CN¥14.57 Million |
| 2023 | 10.61% | 33.09% | 0.24x | 1.31x | CN¥8.49 Million |
| 2024 | 8.97% | 29.13% | 0.24x | 1.29x | CN¥-14.56 Million |
| 2025 | 3.15% | 13.35% | 0.19x | 1.25x | CN¥-96.68 Million |
Industry Comparison
This section compares Chemclin Diagnostics Co. Ltd. A's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $3,051,588,933
- Average return on equity (ROE) among peers: 17.97%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chemclin Diagnostics Co. Ltd. A (688468) | CN¥1.42 Billion | -67.26% | 0.24x | $390.32 Million |
| Berry Genomics Co Ltd (000710) | $1.56 Billion | 14.92% | 0.16x | $453.68 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $7.48 Billion | 15.56% | 1.09x | $1.61 Billion |
| Hangzhou Tigermed Consulting (300347) | $5.52 Billion | 15.24% | 0.37x | $4.29 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $3.27 Billion | 11.90% | 0.41x | $1.07 Billion |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $1.29 Billion | 12.53% | 0.12x | $507.83 Million |
| Maccura Biotechnology Co Ltd (300463) | $6.42 Billion | 1.97% | 0.24x | $836.15 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $501.67 Million | 15.17% | 0.15x | $561.94 Million |
| BGI Genomics Co Ltd (300676) | $4.13 Billion | 9.36% | 0.24x | $2.25 Billion |
| Amoy Diagnostics Co Ltd (300685) | $39.30 Million | 56.11% | 1.81x | $1.18 Billion |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $305.25 Million | 26.97% | 0.85x | $584.32 Million |
About Chemclin Diagnostics Co. Ltd. A
Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on photo-induced chemiluminescence and CC series based on enzymatic chemiluminescence diagnostic reagents and instruments, primarily used for infectious diseases, such a… Read more